Will FDA Labelling Be MannKind's Downfall?
While FDA approval may have come wrapped in a pretty box for shareholders, what is inside the box in terms of FDA warnings could be a huge problem for MannKind and Afrezza.
3 Longtime Losers About to See Green?
These 3 biotechs have lost tons of money every year so far in the 21st century. But could profits be on the horizon?